Bachem Group today announced the signing of a further work order for the delivery of large volumes of peptides for a minimum total of CHF 1 billion over a five-year period from 2025-2029, which follows the conclusion of two large volume contracts announced on 20 September 2022.

 

The companies have agreed not to disclose additional details and respect customer confidentiality.

 

Bachem is pursuing an investment program across all sites to expand capacity. A modern large-scale facility for the manufacture of peptides and oligonucleotides (Building «K» – TIDES FABrication Plant) with the potential to double the manufacturing capacity at the Bubendorf site. A new site in Switzerland is planned in Eiken (canton of Aargau) and is intended to further strengthen the production network from the end of the decade onward. Bachem is also investing into capacity expansion across its global manufacturing network at sites in Vionnaz (Switzerland), Torrance (USA), Vista (USA) and St. Helens (UK).